{
    "symbol": "EBS",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-01 20:07:07",
    "content": " Other notable items in the quarter include: Anthrax vaccine sales of $96 million, higher than the prior year due to timing of deliveries of AV7909 to the U.S. government's Strategic National Stockpile; nasal naloxone product sales of $102 million, slightly lower than the prior year and comprised of significant unit sales of branded NARCAN to U.S. public interest and Canadian customers as well as contributions from sales of the authorized generic product licensed to Sandoz."
}